KŘENOVÁ, Zdenka, Eliška TVRDÍKOVÁ, Jaroslav ŠTĚRBA, Daniela KODYTKOVÁ and Leoš KŘEN. Langerhans cell histiocytosis: intrinsic immunoediting properties. In XXV. Konference dětských hematologů a onkologů České a Slovenské republiky. 2015. ISBN 978-80-210-7958-8.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Langerhans cell histiocytosis: intrinsic immunoediting properties
Authors KŘENOVÁ, Zdenka (203 Czech Republic, guarantor, belonging to the institution), Eliška TVRDÍKOVÁ (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Daniela KODYTKOVÁ (203 Czech Republic, belonging to the institution) and Leoš KŘEN (203 Czech Republic, belonging to the institution).
Edition XXV. Konference dětských hematologů a onkologů České a Slovenské republiky, 2015.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/15:00085104
Organization unit Faculty of Medicine
ISBN 978-80-210-7958-8
Keywords in English langerhans cell histiocytosis; non-classical immunomodulatory molecules; intrinsic immunoediting properties
Tags EL OK
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 7/12/2015 14:58.
Abstract
Non-classical HLA-molecules physiologically protect the fetus from maternal allorecognition, this mechanism seems to be used by some tumors during their development. PD-L1 is physiologically expressed mainly on antigen presenting cells, some types of tumors use this ligand to supress host immune reactions. The expression of non-classical immunomodulatory molecules (HLA-G, HLA-E, HLA-F) as well as the expression of immune checkpoint regulator programmed death ligand (PD-L1) is not characterized in Langerhans cell histiocytosis (LCH). Our data suggest that non-classical immunomodulatory molecules and immune checkpoint molecules may play role in immunoediting process during development of LCH. Further studies regarding immunoediting properties including non-classical HLA molecules and immune checkpoints ligands appear warranted for better understanding and therapy of this enigmatic disorder.
PrintDisplayed: 6/7/2024 19:43